GSK Pharma Analyst Meet Takeaways - A Mixed Bag: Motilal Oswal

“Shingrix” launch soon; WPI to mitigate the impact of price cut under NLEM

<div class="paragraphs"><p>A view shows GlaxoSmithKline headquarters in London, Britain. (Source: Reuters/Hannah McKay)</p></div>
A view shows GlaxoSmithKline headquarters in London, Britain. (Source: Reuters/Hannah McKay)

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.  

Motilal Oswal Report

We attended the analyst meet of GlaxoSmithKline Pharmaceuticals Ltd. to understand the company’s business outlook over the next two to three years.

Key highlights of Analyst Meet

  • GSK Pharma guided for high single-digit revenue growth over FY23-25, driven considerably by volume.

  • While there would be an adverse impact of price reduction due to the inclusion of ‘Ceftum’ and ‘T-Bact’ under the National list of essential medicines, GSK Pharma is expected to mitigate the impact through higher volume sale.

  • Further, the company is focussed on launching its ‘Shingrix’ vaccine. The company’s ongoing cost optimisation measures would also aid in driving up its profitability.

  • Unlike peers in the domestic formulation industry, GSK Pharma is expected to have fewer new launches in the market. It plans to focus on market share gain in its existing products through life cycle management and increasing their reach.

  • The wholesale price index-led price increase is expected from April 2023, which would also partially offset the adverse impact of price reduction under NLEM.

Click on the attachment to read the full report:

Motilal Oswal GSK Pharma Update.pdf
India Pharma - IPM Grew 23.9% In February On Favorable Base: Dolat Capital


This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.